This Core Concepts set covers Class III antiarrhythmic agents: the potassium channel blockers. The group includes amiodarone, sotalol, dofetilide, ibutilide, and dronedarone. These drugs share a common mechanism of prolonging the action potential duration by blocking repolarizing potassium currents, but they differ profoundly in their pharmacokinetics, organ toxicity, safety constraints, and clinical indications. Amiodarone stands apart from the group in its multi-channel mechanism and extraordinary pharmacokinetic complexity. Dofetilide and sotalol carry mandatory in-hospital initiation requirements driven by torsades de pointes risk. Dronedarone is tightly constrained by trial evidence from ANDROMEDA and PALLAS. These questions are designed to establish your foundational knowledge of each agent before you encounter clinical vignettes in higher tiers. Work through each question carefully and use the rationales to build a precise mechanistic map of this drug class.
1. Which of the following best describes the primary antiarrhythmic mechanism shared by all Class III agents?
A) Slowing of phase 0 upstroke velocity in fast-response tissue by sodium channel blockade
B) Prolongation of action potential duration and effective refractory period by blockade of repolarizing potassium currents, eliminating the excitable gap in re-entrant circuits
C) Reduction of spontaneous phase 4 depolarization in the sinoatrial node by calcium channel blockade
D) Competitive antagonism at beta-adrenergic receptors reducing heart rate and AV nodal conduction velocity
E) Enhancement of inward rectifier potassium current accelerating phase 3 repolarization and shortening the refractory period
ANSWER: B
Rationale:
Class III agents prolong the cardiac action potential duration (APD) and effective refractory period (ERP) by blocking repolarizing potassium currents, principally the rapid delayed rectifier IKr. This prolongation of refractoriness eliminates the excitable gap in re-entrant circuits: the circulating wavefront encounters refractory tissue and extinguishes. Unlike Class I agents, Class III drugs do not slow conduction velocity, their mechanism is refractory period extension.
Option A: Option A describes the Class I sodium channel blocking mechanism, which slows phase 0 upstroke velocity and is distinct from Class III action.
Option C: Option C describes the effect of non-dihydropyridine calcium channel blockers on the sinoatrial node: a Class IV mechanism, not Class III.
Option D: Option D describes beta-adrenergic antagonism, which is the Class II mechanism.
Option E: Option E inverts the correct pharmacology: enhancing IKr would shorten repolarization and reduce the refractory period, which is the opposite of Class III antiarrhythmic action.
2. The rapid delayed rectifier potassium current IKr is encoded by which gene, and why is this channel uniquely susceptible to block by a structurally diverse range of drugs beyond dedicated antiarrhythmics?
A) KCNQ1; its slow activation kinetics allow prolonged drug-channel interaction during the phase 2 plateau, making it accessible to a wide range of lipophilic compounds
B) SCN5A; its inactivated-state conformation exposes a promiscuous hydrophobic binding pocket accessible to structurally unrelated compounds during phase 0
C) HCN4; its cyclic nucleotide-binding domain accommodates diverse chemical scaffolds, making it susceptible to off-target drug block across pharmacological classes
D) KCNH2 (hERG); its unusually large inner vestibule and aromatic amino acid residues in the channel pore create high-affinity binding sites accessible to a wide range of drug structures, explaining why antiarrhythmics, antihistamines, antibiotics, and antipsychotics all carry IKr-blocking potential
E) CACNA1C; its extracellular loop contains aromatic residues that bind positively charged drug molecules during depolarization, producing cross-class QT prolongation
ANSWER: D
Rationale:
IKr is encoded by KCNH2, also called hERG (human ether-a-go-go related gene). The hERG channel has an unusually large inner vestibule compared to other potassium channels, and its S6 transmembrane helices contain aromatic amino acid residues, notably tyrosine and phenylalanine, that form high-affinity hydrophobic and pi-stacking interactions with a broad range of chemical structures. This explains why drugs from entirely unrelated pharmacological classes, antihistamines, antibiotics, antipsychotics, and antifungals: all share IKr-blocking potential and QT-prolonging risk.
Option A: Option A incorrectly assigns IKr to KCNQ1, which encodes IKs, the slow delayed rectifier: a distinct repolarizing current targeted by amiodarone but not the primary target of most Class III agents.
Option B: Option B incorrectly identifies SCN5A, which encodes the cardiac sodium channel Nav1.5: a Class I target with no role in IKr pharmacology.
Option C: Option C incorrectly identifies HCN4, which encodes the If pacemaker current in the sinoatrial node and is the target of ivabradine, not Class III agents.
Option E: Option E incorrectly identifies CACNA1C, which encodes the cardiac L-type calcium channel Cav1.2: a Class IV target unrelated to IKr.
3. Which of the following correctly defines reverse use-dependence as it applies to pure IKr-blocking agents and identifies its primary clinical consequence?
A) APD prolongation by pure IKr blockers is greatest at slow heart rates and least at fast rates, because IKr channels spend more time in the closed drug-accessible state during bradycardia: the condition that most favors early afterdepolarization formation and torsades de pointes
B) Pure IKr blockers are eliminated more rapidly during exercise due to increased renal perfusion, reducing antiarrhythmic plasma levels precisely when protection against tachycardia is most needed
C) APD prolongation by pure IKr blockers is uniform across all heart rates, eliminating the pause-dependent risk of torsades de pointes that characterizes agents such as amiodarone
D) At faster heart rates, IKr channel open probability increases, exposing more drug-binding sites and amplifying IKr block during tachycardia when re-entry is most active
E) Reverse use-dependence describes the tendency of Class III agents to terminate triggered arrhythmias at slow rates while remaining ineffective against re-entrant arrhythmias at fast rates
ANSWER: A
Rationale:
Reverse use-dependence means that APD prolongation by pure IKr blockers, dofetilide, ibutilide, and to a lesser extent sotalol, is greatest at slow heart rates and diminishes at rapid rates. IKr channels spend more time in the closed, drug-accessible conformation during bradycardia, maximizing block and APD prolongation at precisely the rate that most favors early afterdepolarization (EAD) formation and torsades de pointes (TdP). The drug provides the least antiarrhythmic effect during tachycardia, when suppression of re-entry is the therapeutic goal. Amiodarone and dronedarone are partial exceptions: their multi-channel profiles reduce reverse use-dependence. Option E mischaracterizes reverse use-dependence as an arrhythmia-type distinction rather than a rate-dependent pharmacodynamic property.
Option B: Option B incorrectly attributes reverse use-dependence to renal elimination kinetics rather than rate-dependent channel pharmacodynamics: this is not the definition of the term.
Option C: Option C inverts the definition: uniform rate-independent APD prolongation is a property of amiodarone, not pure IKr blockers.
Option D: Option D inverts the channel kinetics: hERG channels are more accessible to block in the closed state at slow rates, not in the open state at fast rates.
4. Amiodarone is described as a multi-class antiarrhythmic. Which of the following correctly identifies all four Vaughan Williams class actions it possesses and explains why it has a markedly lower torsades de pointes incidence than dofetilide despite producing greater absolute QT prolongation?
A) Classes I and III only; amiodarone's combined sodium and potassium channel blockade produces uniform APD prolongation that eliminates reverse use-dependence and prevents pause-dependent EAD formation
B) Classes II and III only; amiodarone's beta-blocking activity prevents the bradycardia that triggers torsades de pointes, and its IKr blockade maintains refractoriness, together these account for its low TdP incidence
C) Classes I, II, III, and IV; its concurrent L-type calcium channel (ICaL) blockade reduces the primary inward trigger current for early afterdepolarization formation, counteracting the proarrhythmic effect of action potential prolongation and explaining its low TdP incidence despite marked QT prolongation
D) Classes I, II, III, and IV; its beta-adrenergic blocking activity is the dominant mechanism preventing torsades de pointes by keeping the heart rate above the bradycardic threshold at which EADs form
E) Classes III and IV only; amiodarone's combined IKr and ICaL blockade produces a uniquely stable plateau phase that prevents EAD formation without the sodium channel effects seen with Class I agents
ANSWER: C
Rationale:
Amiodarone encompasses all four Vaughan Williams classes: Class I (tonic sodium channel block slowing conduction in fast-response tissue), Class II (non-competitive beta-adrenergic blockade reducing heart rate and AV nodal conduction), Class III (blockade of IKr, IKs, IK1, and IKAch producing marked APD and ERP prolongation across all cardiac tissues), and Class IV (L-type calcium channel blockade reducing AV nodal conduction velocity and sinus rate). Its low TdP incidence despite marked QT prolongation is best explained by concurrent ICaL blockade: EADs arise when inward currents overcome outward currents during a prolonged action potential plateau, and reducing ICaL directly suppresses the primary inward trigger current for EAD generation. Pure IKr blockers such as dofetilide lack this compensating mechanism. Option D correctly identifies the four classes but incorrectly identifies beta-blockade as the dominant anti-TdP mechanism rather than ICaL blockade.
Option A: Option A incorrectly limits amiodarone to Classes I and III, omitting its beta-blocking and calcium channel blocking actions.
Option B: Option B incorrectly limits amiodarone to Classes II and III and overstates the role of beta-blockade as the explanation for low TdP: ICaL blockade reducing the EAD trigger is the more complete mechanistic answer.
Option E: Option E incorrectly limits amiodarone to Classes III and IV, omitting the Class I sodium channel and Class II beta-blocking components that contribute importantly to its broad efficacy.
5. Which of the following correctly describes the pharmacokinetic properties of amiodarone that most directly determine its dosing strategy and the prolonged persistence of its effects after discontinuation?
A) Oral bioavailability near 100%, volume of distribution 2 to 5 L/kg, elimination half-life 6 to 8 hours, effects resolve within 24 hours of stopping and no loading dose is required
B) Oral bioavailability 90%, elimination entirely by renal excretion unchanged, half-life 12 to 18 hours, dose must be reduced proportionally to creatinine clearance
C) Oral bioavailability 40 to 67%, hepatic CYP3A4 metabolism to an inactive metabolite, half-life 24 to 27 hours, predictable kinetics permit twice-daily dosing without a loading phase
D) Oral bioavailability 20 to 35% due to extensive first-pass metabolism by CYP3A4, half-life 6 to 8 hours, active metabolite norverapamil contributing approximately 20% of parent activity
E) Oral bioavailability 22 to 86% (highly variable), volume of distribution 60 to 100 L/kg due to extreme lipophilicity, elimination half-life 40 to 55 days, loading protocols are mandatory for rapid effect and drug effects persist weeks to months after discontinuation
ANSWER: E
Rationale:
Amiodarone has the most unusual pharmacokinetics of any commonly used antiarrhythmic. Its oral bioavailability is highly variable at 22 to 86%, its volume of distribution is extraordinary at 60 to 100 L/kg due to extreme lipophilicity and accumulation in virtually every tissue compartment, and its elimination half-life of 40 to 55 days means effects persist for weeks to months after discontinuation. Loading doses are mandatory when rapid antiarrhythmic effect is needed.
Option A: Option A describes an agent with properties opposite to amiodarone, near-complete bioavailability, small volume of distribution, and a half-life measured in hours. None of these apply to amiodarone.
Option B: Option B describes sotalol's pharmacokinetic profile, approximately 90% bioavailability, complete renal elimination unchanged, and a half-life of 12 to 18 hours.
Option C: Option C describes dronedarone's pharmacokinetic profile: the non-iodinated amiodarone analogue developed specifically to have more predictable kinetics, a shorter half-life, and no requirement for loading.
Option D: Option D describes verapamil's pharmacokinetic profile: 20 to 35% oral bioavailability from first-pass CYP3A4 metabolism, a 6 to 8 hour half-life, and the active metabolite norverapamil.
6. Which of the following correctly identifies amiodarone's most serious organ toxicity and the monitoring strategy required to detect it at an early, treatable stage?
A) Corneal microdeposits detectable on slit-lamp examination in over 90% of patients on long-term therapy: the drug must be discontinued at first detection to prevent irreversible visual loss
B) Pulmonary toxicity presenting as interstitial pneumonitis or bronchiolitis obliterans, monitoring requires annual chest X-ray and pulmonary function tests at baseline and yearly, with high-resolution CT and drug discontinuation if toxicity is confirmed
C) Hepatic cirrhosis developing in the majority of patients within the first 2 years of therapy, liver biopsy is required at baseline and every 12 months to detect early fibrosis before clinical manifestation
D) Peripheral neuropathy progressing to irreversible motor deficits in most patients on long-term therapy, nerve conduction studies are required every 6 months and the drug must be stopped at first symptom
E) Slate-gray skin discoloration in sun-exposed areas requiring drug discontinuation, dermatology referral is mandatory as this finding predicts imminent pulmonary and hepatic involvement
ANSWER: B
Rationale:
Pulmonary toxicity, presenting as interstitial pneumonitis, bronchiolitis obliterans, or acute respiratory distress, is the most serious organ toxicity associated with amiodarone. Incidence is approximately 1 to 5% per year and increases with cumulative dose and duration. Monitoring requires baseline and annual chest X-ray and pulmonary function tests; high-resolution CT is indicated when symptoms such as dyspnea, nonproductive cough, or fever develop. Drug discontinuation is required if toxicity is confirmed; corticosteroids are used in severe cases.
Option A: Option A describes corneal microdeposits, which occur in over 90% of patients on long-term amiodarone but are not themselves an indication to discontinue the drug: they rarely impair visual acuity, and discontinuation is warranted only for the rare complication of optic neuropathy, not for deposits alone.
Option C: Option C overstates the hepatic toxicity risk, clinically significant cirrhosis is a rare late complication of high-dose long-term use, occurring in under 1% of patients, and routine liver biopsy is not required; liver function tests every 6 months are the standard monitoring tool.
Option D: Option D overstates both the incidence and severity of peripheral neuropathy: it occurs in approximately 3 to 5% of patients and does not progress to irreversible motor deficits in most cases; nerve conduction studies are not required every 6 months as a routine monitoring protocol.
Option E: Option E describes slate-gray skin discoloration, which is a cosmetic finding that is usually irreversible but does not mandate drug discontinuation and does not predict pulmonary or hepatic involvement.
7. A patient stable on warfarin with an INR of 2.3 is started on amiodarone for ventricular arrhythmia suppression. Six weeks later her INR has risen to 5.2. Which of the following correctly identifies the mechanism of this interaction and the appropriate management response?
A) Amiodarone induces hepatic CYP2C9, accelerating S-warfarin metabolism and producing erratic INR fluctuations, warfarin should be stopped and a direct oral anticoagulant substituted immediately
B) Amiodarone displaces warfarin from its vitamin K epoxide reductase binding site, directly augmenting its anticoagulant effect independently of plasma drug levels, dose separation by 4 hours eliminates the interaction
C) Amiodarone's active metabolite desethylamiodarone directly inhibits clotting factor synthesis in hepatocytes, producing an additive anticoagulant effect that is not reversible by warfarin dose reduction alone
D) Amiodarone inhibits CYP2C9, reducing metabolism of S-warfarin (the pharmacologically active enantiomer), and also displaces warfarin from albumin binding sites raising free warfarin concentration: the appropriate response is to reduce the warfarin dose by one-third to one-half and monitor INR closely for 4 to 8 weeks
E) Amiodarone inhibits intestinal P-glycoprotein, increasing warfarin oral bioavailability and raising peak plasma levels: the interaction resolves within 2 weeks as amiodarone reaches steady state
ANSWER: D
Rationale:
Amiodarone inhibits CYP2C9, the primary enzyme responsible for metabolism of S-warfarin: the pharmacologically active enantiomer that accounts for most of warfarin's anticoagulant effect. This reduces warfarin clearance and raises INR. Additionally, amiodarone displaces warfarin from albumin binding sites, further increasing free warfarin concentration. The interaction is delayed by weeks because of amiodarone's extraordinary tissue accumulation kinetics, CYP2C9 inhibition builds gradually as amiodarone accumulates in tissue. Standard management is to reduce the warfarin dose by one-third to one-half when amiodarone is started and to monitor INR closely for 4 to 8 weeks and at intervals thereafter given amiodarone's prolonged half-life. Option B is pharmacologically incorrect: amiodarone does not bind to vitamin K epoxide reductase and the interaction cannot be eliminated by dose separation.
Option A: Option A inverts the mechanism: amiodarone inhibits CYP2C9, it does not induce it, induction would reduce warfarin effect, not increase it, and switching anticoagulants is not the standard response.
Option C: Option C is incorrect: desethylamiodarone does not directly inhibit clotting factor synthesis: the interaction is entirely pharmacokinetic via CYP2C9 inhibition and albumin displacement, and it is managed by warfarin dose reduction.
Option E: Option E incorrectly describes the mechanism as intestinal P-glycoprotein inhibition affecting bioavailability, warfarin's interaction with amiodarone is a metabolic CYP2C9 interaction, not a bioavailability interaction, and the effect does not resolve at steady state.
8. A patient on digoxin 0.125 mg daily for rate control in atrial fibrillation is started on amiodarone. Which of the following correctly identifies the mechanism by which amiodarone raises digoxin serum levels and the appropriate management response?
A) Amiodarone inhibits P-glycoprotein and reduces digoxin renal tubular clearance, raising digoxin serum levels by approximately 70 to 100%: the digoxin dose should be halved and serum levels rechecked within 1 to 2 weeks
B) Amiodarone induces renal CYP3A4, increasing digoxin hydroxylation and biliary excretion: this reduces digoxin levels unpredictably, requiring a 25% dose increase to maintain therapeutic concentrations
C) Amiodarone competitively displaces digoxin from its Na+/K+-ATPase binding site in cardiac tissue, reducing its inotropic and rate-slowing effects despite an apparent rise in serum levels
D) Amiodarone induces intestinal P-glycoprotein, reducing digoxin oral bioavailability and creating trough-level fluctuations that require twice-weekly therapeutic drug monitoring
E) Amiodarone reduces digoxin renal elimination by impairing glomerular filtration through a vasoconstrictive renal effect, separating the doses by 4 hours and monitoring renal function monthly is sufficient management
ANSWER: A
Rationale:
Amiodarone inhibits P-glycoprotein (P-gp) at both the intestinal and renal tubular level and reduces digoxin renal tubular secretion by an additional mechanism, together raising digoxin serum levels by approximately 70 to 100%, roughly doubling digoxin exposure. The appropriate response is to halve the digoxin dose when amiodarone is started and to recheck serum digoxin levels within 1 to 2 weeks. Option C is pharmacologically incorrect: amiodarone does not competitively displace digoxin from Na+/K+-ATPase; the elevated serum levels represent genuine pharmacokinetic accumulation with full receptor occupancy and activity, not a binding displacement artifact.
Option B: Option B inverts the mechanism: amiodarone inhibits P-glycoprotein, it does not induce renal CYP3A4, digoxin is not significantly metabolized by CYP enzymes and a dose increase would precipitate toxicity rather than restore therapeutic levels.
Option D: Option D inverts the P-glycoprotein effect: amiodarone inhibits, not induces, intestinal P-gp: the net effect is increased digoxin absorption and reduced renal clearance, both raising levels.
Option E: Option E incorrectly attributes the interaction to a vasoconstrictive renal mechanism reducing glomerular filtration: the primary interaction is P-gp inhibition and reduced tubular secretion, and dose separation does not resolve a systemic pharmacokinetic interaction.
9. Which of the following correctly describes the basis of amiodarone-associated thyroid toxicity and the monitoring strategy required during long-term therapy?
A) Amiodarone's non-competitive beta-blocking activity suppresses TSH secretion from the pituitary, producing central hypothyroidism, measurement of TSH alone is sufficient for annual monitoring
B) Amiodarone competes with thyroxine for plasma protein binding, raising free T4 levels as a pharmacokinetic artifact: this does not represent true thyroid dysfunction and requires no specific monitoring or treatment
C) Amiodarone contains approximately 37% iodine by weight and releases large quantities of inorganic iodine during metabolism, which can precipitate either hypothyroidism or hyperthyroidism depending on the underlying thyroid status, thyroid function tests are required every 6 months throughout therapy and for at least 12 months after discontinuation
D) Amiodarone induces autoimmune thyroiditis exclusively by presenting iodinated neoantigens to thyroid follicular cells, producing a Hashimoto-like pattern, monitoring with antithyroid peroxidase antibodies every 12 months is sufficient
E) Amiodarone's hepatic metabolite desethylamiodarone selectively inhibits thyroid peroxidase, producing dose-dependent hypothyroidism in all patients within the first 6 months of therapy, prophylactic levothyroxine should be started at amiodarone initiation
ANSWER: C
Rationale:
Amiodarone contains approximately 37% iodine by weight. A single 200 mg tablet releases roughly 75 mg of inorganic iodine during metabolism, far exceeding normal dietary intake. This iodine load can produce hypothyroidism (the most common thyroid complication, occurring in 6 to 10% of patients, as excess iodide inhibits thyroid hormone synthesis via the Wolff-Chaikoff effect) or hyperthyroidism (2 to 3% of patients, either through iodine-induced autonomous hormone production in nodular glands or through a destructive thyroiditis pattern). Because either direction of thyroid dysfunction is possible, TSH and free thyroid hormones must be checked every 6 months throughout therapy and for at least 12 months after stopping given amiodarone's prolonged tissue half-life.
Option A: Option A is incorrect: amiodarone's beta-blocking activity does not cause clinically meaningful TSH suppression, thyroid abnormalities in amiodarone-treated patients reflect true thyroid dysfunction from the iodine load and direct thyroid effects.
Option B: Option B incorrectly dismisses the thyroid effects as a protein-binding artifact requiring no management, thyroid dysfunction from amiodarone is a genuine clinical syndrome with defined incidence and treatment protocols.
Option D: Option D incorrectly limits amiodarone thyrotoxicosis to an autoimmune Hashimoto-like pattern: two distinct types of amiodarone-induced thyrotoxicosis exist (iodine-driven and destructive), and antibody monitoring alone is not the required strategy.
Option E: Option E incorrectly states that desethylamiodarone selectively inhibits thyroid peroxidase and that hypothyroidism develops in all patients, thyroid toxicity is not universal and the mechanism involves the iodine load, not selective peroxidase inhibition.
10. Sotalol differs from all other beta-blockers used in cardiology by possessing a second distinct antiarrhythmic mechanism. Which of the following correctly identifies this dual pharmacology and explains why it requires in-hospital initiation?
A) Sotalol adds Class IV L-type calcium channel blockade to its beta-blocking activity, producing additive AV nodal slowing that can precipitate complete heart block, continuous telemetry for the first 24 hours is required
B) Sotalol adds Class I sodium channel blockade to its beta-blocking activity, slowing ventricular conduction velocity and producing QRS widening that must be monitored during the first 48 hours of dosing
C) Sotalol adds alpha-1 adrenergic blockade to its beta-blocking activity, producing peripheral vasodilation that can precipitate orthostatic hypotension severe enough to require hemodynamic monitoring at initiation
D) Sotalol adds activity at a second beta-receptor subtype (beta-3) to its primary beta-1 and beta-2 blockade, producing metabolic effects on adipose and skeletal muscle that require baseline metabolic monitoring before initiation
E) Sotalol adds Class III IKr blockade to its beta-blocking activity: the l-isomer provides non-selective beta-adrenergic blockade while both d- and l-isomers block IKr, prolonging QTc with a 2 to 4% torsades de pointes risk that requires a minimum of 3 days of in-hospital continuous monitoring with telemetry
ANSWER: E
Rationale:
Sotalol is a racemic mixture of d- and l-sotalol. The l-isomer provides non-selective beta-adrenergic blockade (Class II), while both d- and l-isomers block the rapid delayed rectifier potassium current IKr (Class III). This combined Class II plus Class III mechanism gives sotalol a unique dual profile: rate slowing via beta-blockade combined with action potential duration prolongation via IKr blockade. The IKr blockade produces dose-dependent QTc prolongation with a torsades de pointes risk of approximately 2 to 4%. Because TdP is most likely to occur during the first several days of initiation and is amplified by QTc prolongation, bradycardia, hypokalemia, hypomagnesemia, and renal impairment, guidelines require initiation or re-initiation in a facility capable of continuous cardiac monitoring for a minimum of 3 days.
Option A: Option A incorrectly attributes the second mechanism to Class IV calcium channel blockade, sotalol does not block L-type calcium channels and does not require monitoring for AV block as its primary initiation concern.
Option B: Option B incorrectly attributes the second mechanism to Class I sodium channel blockade, sotalol does not slow ventricular conduction velocity or widen the QRS.
Option C: Option C incorrectly attributes alpha-1 adrenergic blockade to sotalol, sotalol is a pure beta-blocker without alpha-1 activity; this combined blockade profile describes labetalol and carvedilol.
Option D: Option D incorrectly attributes a beta-3 receptor mechanism and metabolic monitoring requirement to sotalol, sotalol's second mechanism is IKr blockade, not beta-3 activity.
11. A patient with persistent atrial fibrillation and a creatinine clearance of 35 mL/min is being evaluated for sotalol for rhythm control. Which of the following correctly applies sotalol's pharmacokinetic profile to this clinical situation?
A) Sotalol requires a 50% dose reduction in this patient because it undergoes hepatic CYP2D6 metabolism that is secondarily impaired when renal blood flow falls, standard dosing at reduced frequency is appropriate
B) Sotalol is contraindicated in this patient because it is eliminated entirely unchanged by the kidneys, at a creatinine clearance below 40 mL/min, drug accumulation prolongs the half-life, amplifies QTc prolongation, and creates an unacceptable torsades de pointes risk
C) Sotalol can be used at the standard dose of 80 mg twice daily because its renal dosing threshold applies only to patients with a creatinine clearance below 20 mL/min
D) Sotalol requires an extended dosing interval of every 36 to 48 hours in this patient, as this adjustment is appropriate across the full range of creatinine clearance values below 60 mL/min
E) Sotalol is acceptable at a reduced dose of 40 mg twice daily with weekly outpatient QTc monitoring, because low-dose sotalol carries a negligible torsades de pointes risk regardless of renal function
ANSWER: B
Rationale:
Sotalol is eliminated entirely unchanged by the kidneys, with no meaningful hepatic metabolism. Its oral bioavailability is approximately 90% and its half-life of 12 to 18 hours extends proportionally as renal function declines, because drug accumulation directly correlates with the degree of renal impairment. The guideline contraindication threshold is a creatinine clearance of 40 mL/min, below this level, accumulation raises plasma levels, amplifies QTc prolongation, and creates an unacceptable TdP risk. This patient's CrCl of 35 mL/min falls below that threshold, making sotalol contraindicated.
Option A: Option A is incorrect on mechanism: sotalol does not undergo hepatic CYP2D6 metabolism: it is renally eliminated unchanged, and reduced renal blood flow is not the relevant concept; the contraindication is based on CrCl below 40 mL/min.
Option C: Option C incorrectly states the contraindication threshold as CrCl below 20 mL/min: the established threshold is below 40 mL/min, and standard dosing at CrCl 35 mL/min would cause accumulation and elevated TdP risk.
Option D: Option D describes an interval-extension approach that applies to patients with CrCl between 40 and 60 mL/min: this patient's CrCl of 35 mL/min is below the 40 mL/min contraindication threshold, so interval extension is not an appropriate solution.
Option E: Option E is incorrect: drug accumulation from reduced renal elimination raises effective plasma levels regardless of the starting dose, and outpatient QTc monitoring does not substitute for the renal contraindication.
12. Which of the following correctly describes dofetilide's mechanism of action, its mandatory initiation requirements, and the regulatory system governing its prescription in the United States?
A) Dofetilide blocks IKr and IKs with equal potency; initiation requires a 24-hour observation period with QTc monitoring, and prescribers must complete a one-time online training module before writing the first prescription
B) Dofetilide blocks IKr and IKs with mild additional sodium channel activity at higher doses; it is available through any pharmacy once the prescriber has obtained hospital admitting privileges
C) Dofetilide is a non-selective potassium channel blocker with additional muscarinic receptor antagonism; it does not require in-hospital initiation but mandates weekly outpatient ECG monitoring for the first month
D) Dofetilide is a highly selective pure IKr blocker with no adrenergic, calcium channel, or sodium channel activity; all patients must be initiated in a facility capable of continuous monitoring for at least 3 days with QTc checked after each dose, and prescribers must be certified through the Tikosyn In Pharmacy System
E) Dofetilide selectively blocks IKs while sparing IKr, producing rate-independent APD prolongation without reverse use-dependence; initiation requires 48 hours of in-hospital monitoring and is available without prescriber certification
ANSWER: D
Rationale:
Dofetilide is a highly selective, pure IKr blocker with no adrenergic, calcium channel, or sodium channel activity. Its selectivity produces predictable, dose-proportional QT prolongation with a TdP risk of approximately 1 to 3%. All patients must be initiated in a facility capable of continuous cardiac monitoring for at least 3 days, with QTc checked 2 to 3 hours after each dose; if QTc exceeds 500 ms, the dose must be reduced or the drug discontinued. In the United States, prescribers must be certified through the Tikosyn In Pharmacy System (TIPS), a mandatory prescriber education and registry program that also restricts dispensing to certified pharmacies.
Option A: Option A incorrectly states that dofetilide blocks both IKr and IKs, dofetilide is a pure IKr blocker, and the initiation duration and training requirements described are also incorrect.
Option B: Option B incorrectly attributes sodium channel activity to dofetilide and incorrectly states that general hospital privileges replace the TIPS certification requirement.
Option C: Option C incorrectly attributes muscarinic receptor antagonism to dofetilide and incorrectly states that in-hospital initiation is not required: it is mandated by prescribing guidelines.
Option E: Option E inverts dofetilide's mechanism: it blocks IKr, not IKs, IKs blockade is a property of amiodarone, and the initiation duration and certification requirements in Option E are both incorrect.
13. A patient with heart failure with reduced ejection fraction (EF 28%) and paroxysmal atrial fibrillation requires rhythm control after two electrical cardioversions have failed to maintain sinus rhythm. Which trial evidence supports dofetilide as an acceptable agent in this patient and what does it demonstrate?
A) The DIAMOND-CHF trial enrolled patients with heart failure and ejection fraction below 35% and demonstrated that dofetilide did not increase all-cause mortality compared to placebo, while also converting a significant proportion of patients to sinus rhythm during in-hospital initiation, establishing it as one of two antiarrhythmic agents considered safe for rhythm control in HFrEF
B) The CAST trial demonstrated that dofetilide, unlike flecainide and encainide, did not increase mortality after myocardial infarction: this post-MI safety evidence is considered sufficient to support its use in heart failure with reduced ejection fraction
C) The PALLAS trial demonstrated that dofetilide did not cause excess mortality in patients with permanent atrial fibrillation and structural heart disease, distinguishing it from dronedarone and establishing its safety in the HFrEF population
D) The ATHENA trial demonstrated that dofetilide reduced cardiovascular hospitalization and cardiovascular death in patients with atrial fibrillation and structural heart disease, including those with reduced ejection fraction
E) The SWORD trial demonstrated that pure IKr blockers without beta-blocking activity are safer than combined Class II/III agents in left ventricular dysfunction, and dofetilide was subsequently approved for HFrEF on the basis of this mechanistic extrapolation
ANSWER: A
Rationale:
The DIAMOND-CHF (Danish Investigations of Arrhythmia and Mortality on Dofetilide in CHF) trial enrolled patients with symptomatic congestive heart failure and ejection fraction below 35%. It demonstrated that dofetilide did not increase all-cause mortality compared to placebo: a critical finding given that flecainide, propafenone, sotalol, and dronedarone all carry mortality signals or contraindications in this population. A significant proportion of patients converted to sinus rhythm during in-hospital initiation. This neutral mortality finding, together with amiodarone's safety data, establishes dofetilide as one of only two antiarrhythmic agents considered appropriate for rhythm control in HFrEF.
Option B: Option B incorrectly attributes the relevant evidence to the CAST trial, CAST studied flecainide and encainide post-MI and established their excess mortality risk; dofetilide was not studied in CAST and post-MI safety data does not substitute for HFrEF-specific evidence.
Option C: Option C incorrectly attributes the evidence to PALLAS, PALLAS studied dronedarone in permanent AF and demonstrated excess mortality with dronedarone, not dofetilide safety in HFrEF.
Option D: Option D incorrectly attributes the evidence to ATHENA, ATHENA established dronedarone's reduction in cardiovascular hospitalization in patients with non-permanent AF and preserved or mildly reduced EF, not dofetilide's safety in HFrEF.
Option E: Option E incorrectly describes SWORD as the basis for dofetilide's approval, SWORD studied d-sotalol and demonstrated increased mortality in LV dysfunction, which if anything argues against pure IKr blockers; dofetilide's safety in HFrEF was established by DIAMOND-CHF specifically.
14. A patient stabilized on dofetilide for atrial fibrillation is admitted for an uncomplicated urinary tract infection. The treating team considers several antibiotic options. Which of the following represents a contraindicated combination with dofetilide and correctly identifies the mechanism?
A) Azithromycin, because it is a potent CYP3A4 inhibitor that reduces dofetilide hepatic metabolism, raising plasma dofetilide levels by approximately 60% and creating an unacceptable torsades de pointes risk
B) Amoxicillin, because beta-lactam antibiotics competitively inhibit dofetilide binding at the IKr channel pore, paradoxically reducing its antiarrhythmic effect and increasing arrhythmia recurrence risk
C) Trimethoprim, because it inhibits renal cation transport via the organic cation transporter 2 (OCT2), reducing dofetilide renal tubular secretion and substantially raising plasma dofetilide levels, increasing QTc prolongation and torsades de pointes risk
D) Nitrofurantoin, because it induces hepatic CYP2D6 and accelerates dofetilide conversion to a toxic metabolite that directly prolongs the QT interval independently of the parent drug level
E) Ciprofloxacin, because it displaces dofetilide from plasma albumin binding sites, acutely raising free dofetilide concentration to toxic levels within 2 hours of the first dose
ANSWER: C
Rationale:
Dofetilide is 80% renally eliminated unchanged via renal tubular secretion, primarily through the organic cation transporter 2 (OCT2). Drugs that inhibit OCT2 reduce dofetilide secretion, causing accumulation, amplified QTc prolongation, and substantially elevated TdP risk. Trimethoprim is an explicit OCT2 inhibitor and is listed as a contraindicated combination in dofetilide prescribing guidelines. Other contraindicated agents include verapamil, cimetidine, ketoconazole, and megestrol: all of which inhibit OCT2 or reduce renal dofetilide elimination by related mechanisms. Option B is pharmacologically incorrect: beta-lactam antibiotics have no known interaction with IKr channels and no established pharmacokinetic or pharmacodynamic interaction with dofetilide.
Option A: Option A incorrectly identifies azithromycin as the primary concern via CYP3A4 inhibition of dofetilide metabolism, dofetilide is primarily renally eliminated via OCT2, not hepatically metabolized by CYP3A4, so CYP3A4 inhibition has a smaller effect on its levels than OCT2 inhibition. Azithromycin does prolong QT independently and should be avoided, but the mechanism described does not correctly characterize the primary dofetilide interaction pathway.
Option D: Option D is incorrect: nitrofurantoin does not induce CYP2D6, and dofetilide does not have a QT-prolonging active metabolite generated by this pathway.
Option E: Option E is incorrect: dofetilide is not significantly protein-bound in a manner that creates clinically meaningful displacement interactions, and ciprofloxacin does not act via this mechanism.
15. Ibutilide is distinguished from other Class III agents by a unique additional ionic mechanism beyond IKr blockade. Which of the following correctly identifies this mechanism and explains its clinical significance for acute pharmacologic cardioversion?
A) Ibutilide blocks both IKr and IKs simultaneously, producing more complete phase 3 repolarization blockade than pure IKr agents: this dual blockade lowers its torsades de pointes risk compared to dofetilide by preventing excessive transmural APD heterogeneity
B) Ibutilide activates IK1 inward rectifier channels in addition to blocking IKr, shortening the final phase of repolarization to a level that terminates re-entrant circuits without prolonging QTc or requiring post-infusion monitoring
C) Ibutilide inhibits late inward sodium current in addition to blocking IKr, reducing the early afterdepolarization trigger current and producing the lowest torsades de pointes incidence among all Class III agents
D) Ibutilide activates L-type calcium channels in addition to blocking IKr, raising intracellular calcium to a level that terminates triggered arrhythmias by accelerating calcium-dependent afterhyperpolarization
E) Ibutilide activates a slow, sustained inward sodium current in addition to blocking IKr: this combined action produces rapid, potent APD prolongation effective for acute pharmacologic cardioversion of atrial flutter (65 to 70% success rate) and atrial fibrillation (40 to 60%), with a 4 to 8% torsades de pointes risk requiring 4-hour post-infusion cardiac monitoring
ANSWER: E
Rationale:
Ibutilide's mechanism includes IKr blockade combined with activation of a slow, sustained inward sodium current: a mechanism unique among Class III agents. This dual action produces rapid and potent action potential duration prolongation effective for acute pharmacologic cardioversion. Its success rate for atrial flutter is approximately 65 to 70%, higher than for atrial fibrillation (40 to 60%), because flutter's organized re-entrant circuit is more susceptible to refractoriness-based termination than the multiple wavelets of AF. The TdP risk of 4 to 8% is the highest among Class III agents, requiring mandatory continuous cardiac monitoring for at least 4 hours post-infusion with resuscitation equipment immediately available.
Option A: Option A incorrectly states that ibutilide blocks both IKr and IKs, ibutilide's second mechanism is activation of a slow inward sodium current, not IKs blockade, and its TdP risk is the highest, not lowest, among Class III agents.
Option B: Option B inverts the mechanism: ibutilide does not activate IK1 (which would shorten the action potential): it activates a slow inward sodium current that prolongs it, and post-infusion monitoring is mandatory.
Option C: Option C incorrectly attributes late INa blockade to ibutilide: this is the mechanism of ranolazine; ibutilide activates a slow inward sodium current, which is distinct, and its TdP incidence is the highest among Class III agents, not the lowest.
Option D: Option D incorrectly attributes L-type calcium channel activation to ibutilide, ibutilide does not activate ICaL, and this mechanism does not correspond to any established pharmacology of the drug.
16. A patient receiving IV ibutilide for cardioversion of recent-onset atrial flutter develops a polymorphic wide-complex tachycardia with a twisting QRS axis 15 minutes after the infusion. The rhythm is confirmed as torsades de pointes. What is the most appropriate immediate pharmacologic intervention?
A) IV amiodarone 150 mg over 10 minutes to provide counter-regulatory multi-channel blockade and suppress the triggered activity driving torsades de pointes
B) IV magnesium sulfate 2 g over 1 to 2 minutes as first-line treatment, regardless of the serum magnesium level, because magnesium suppresses early afterdepolarizations by blocking the ICaL trigger current
C) IV dofetilide to extend the effective refractory period beyond the vulnerable window and prevent re-initiation of the arrhythmia after spontaneous termination
D) IV adenosine 6 mg as a rapid bolus to terminate the re-entrant circuit sustaining torsades de pointes by producing transient AV nodal block
E) IV lidocaine 1.5 mg/kg to shorten action potential duration in the ventricle and eliminate the prolonged repolarization window responsible for early afterdepolarization formation
ANSWER: B
Rationale:
TdP is an early afterdepolarization-mediated triggered arrhythmia. IV magnesium sulfate 2 g over 1 to 2 minutes is the first-line treatment regardless of serum magnesium level, magnesium suppresses EADs by blocking ICaL, the primary inward trigger current for EAD generation, and also reduces persistent late sodium current. Magnesium terminates TdP in approximately 80% of episodes. If TdP is recurrent and pause-dependent, increasing heart rate with IV isoproterenol or temporary overdrive pacing at 90 to 110 bpm is the next step.
Option A: Option A is incorrect: amiodarone prolongs the QT interval and would worsen the proarrhythmic substrate driving TdP, adding a QT-prolonging agent to an already prolonged QT is contraindicated.
Option C: Option C is incorrect: dofetilide is a pure IKr blocker that further prolongs QTc, administering it during active TdP would dramatically amplify the proarrhythmic risk and is absolutely contraindicated.
Option D: Option D is incorrect: adenosine acts on the AV node and is ineffective for ventricular tachyarrhythmias; TdP is a ventricular arrhythmia driven by EADs in myocardial tissue, not a re-entrant circuit through the AV node.
Option E: Option E is incorrect: while lidocaine shortens APD and may theoretically reduce EAD formation, it is not the established first-line treatment for TdP and its effect in this context is less reliable and less immediate than IV magnesium.
17. Which of the following best explains why amiodarone has a markedly lower incidence of torsades de pointes than dofetilide despite producing greater absolute QT prolongation?
A) Amiodarone's non-competitive beta-blocking activity prevents the bradycardia that most commonly triggers torsades de pointes, eliminating the pause-dependent window for early afterdepolarization formation
B) Amiodarone reduces reverse use-dependence by blocking IKs in addition to IKr, producing more uniform APD prolongation across heart rates and eliminating the slow-rate vulnerability to early afterdepolarization formation
C) Amiodarone's extremely long half-life of 40 to 55 days ensures that plasma levels remain stable without trough fluctuations: it is the pharmacokinetic predictability rather than any ion channel property that accounts for the low TdP rate
D) Amiodarone's concurrent ICaL blockade reduces the primary inward trigger current for early afterdepolarization formation, directly counteracting the proarrhythmic effect of action potential prolongation and explaining its low TdP incidence despite marked QT prolongation
E) Amiodarone's Class I sodium channel blockade slows conduction velocity in ventricular tissue, reducing the rate of spread of triggered impulses originating from early afterdepolarizations before they can sustain torsades de pointes
ANSWER: D
Rationale:
EADs arise when inward currents overcome outward currents during a prolonged action potential plateau or phase 3. The primary inward trigger current for EAD generation is ICaL (L-type calcium channel current). Amiodarone's concurrent ICaL blockade directly reduces this trigger current, suppressing EAD formation despite prolonging APD. Pure IKr blockers such as dofetilide lack this compensating mechanism: they prolong APD without reducing the EAD trigger, leaving the membrane vulnerable to triggered activity. This ICaL mechanism is the most complete and mechanistically precise explanation for amiodarone's paradoxically low TdP incidence. Option A has partial truth, beta-blockade does prevent bradycardia-associated pauses that favor TdP, but this is not the dominant mechanistic explanation and does not account for amiodarone's low TdP rate across all heart rates. Option B correctly identifies that IKs blockade reduces reverse use-dependence, contributing to more uniform APD prolongation, but this explains rate-independence of the QT effect rather than the low TdP incidence specifically.
Option C: Option C is incorrect: the prolonged half-life ensures stable plasma levels but has no direct mechanistic role in preventing EAD formation, pharmacokinetic stability alone does not explain the low TdP rate.
Option E: Option E is incorrect: Class I sodium channel blockade slows conduction but does not prevent EAD formation at the cellular level: it reduces conduction of triggered impulses, which is a different mechanism from suppressing the EAD trigger itself.
18. Which of the following correctly identifies the trial evidence that established a contraindication to dronedarone in permanent atrial fibrillation and describes what that trial demonstrated?
A) The PALLAS trial enrolled patients with permanent atrial fibrillation and cardiovascular risk factors and was stopped early due to excess rates of stroke, cardiovascular death, and arrhythmia in the dronedarone arm, establishing permanent AF as an absolute contraindication to dronedarone
B) The ATHENA trial demonstrated that dronedarone increased stroke risk specifically in patients with permanent atrial fibrillation who had failed rhythm control, leading to a labeling contraindication based on a post-hoc subgroup analysis
C) The ANDROMEDA trial enrolled patients with permanent atrial fibrillation and severe heart failure and demonstrated excess mortality in the dronedarone arm, leading to the contraindication being applied to all patients with permanent AF regardless of ejection fraction
D) The CAST trial demonstrated that dronedarone, like flecainide and propafenone, increased mortality when used in patients with structural heart disease and permanent atrial fibrillation: this class-effect evidence supports the contraindication
E) The AFFIRM trial demonstrated that dronedarone was inferior to rate control alone in patients with permanent atrial fibrillation and increased thromboembolic events: the contraindication derives from this head-to-head comparison with standard therapy
ANSWER: A
Rationale:
The PALLAS (Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy) trial enrolled patients with permanent AF and additional cardiovascular risk factors. It was stopped early due to a significant increase in the rates of stroke, cardiovascular death, and arrhythmia-related events in the dronedarone arm compared to placebo. This finding established permanent AF as an absolute contraindication to dronedarone: the drug is indicated only for non-permanent (paroxysmal or persistent) AF in patients without HFrEF or recent decompensation.
Option B: Option B incorrectly attributes the permanent AF contraindication to ATHENA, ATHENA enrolled patients with non-permanent AF and demonstrated cardiovascular benefit with dronedarone; it did not establish the permanent AF contraindication.
Option C: Option C conflates two distinct trials: ANDROMEDA enrolled patients with severe HFrEF (not permanent AF specifically) and demonstrated excess mortality in that population: it established the HFrEF contraindication, not the permanent AF contraindication.
Option D: Option D incorrectly attributes the evidence to the CAST trial, CAST studied flecainide and encainide post-MI in patients with ventricular arrhythmias, not dronedarone in permanent AF.
Option E: Option E incorrectly attributes the contraindication to AFFIRM: AFFIRM compared rate control to rhythm control strategies broadly and did not study dronedarone specifically.
19. A patient with NYHA Class II heart failure, ejection fraction 34%, and paroxysmal atrial fibrillation asks about dronedarone, which a colleague is taking for AF. Which of the following correctly applies the trial evidence constraining dronedarone use to this patient's situation?
A) Dronedarone is acceptable in this patient because the ANDROMEDA contraindication applies only to patients with NYHA Class IV heart failure: Class II heart failure is explicitly within the approved indication
B) Dronedarone is acceptable because the ATHENA trial enrolled patients with structural heart disease including reduced ejection fraction, and ATHENA demonstrated cardiovascular benefit in this population without excess mortality
C) Dronedarone is contraindicated because the ANDROMEDA trial demonstrated excess mortality with dronedarone in patients with severe HFrEF or recently decompensated heart failure, and current guidelines extend this contraindication to patients with NYHA Class III or IV HF or any recent decompensation: this patient's EF of 34% and HFrEF diagnosis place him in a high-risk category where dronedarone should not be used
D) Dronedarone is contraindicated only if the patient's ejection fraction falls below 25%, at an EF of 34%, the ANDROMEDA mortality signal does not apply and dronedarone can be prescribed with monthly echocardiographic monitoring
E) Dronedarone is acceptable as long as the patient's AF remains paroxysmal rather than permanent, because the PALLAS contraindication applies exclusively to permanent AF regardless of ejection fraction or heart failure status
ANSWER: C
Rationale:
The ANDROMEDA trial enrolled patients with severe HFrEF or recently decompensated heart failure and was stopped early due to excess mortality in the dronedarone arm, likely related to dronedarone's negative inotropic effect and Na+/Ca2+ exchanger inhibition impairing compensation in severely failing hearts. Current ESC and ACC/AHA guidelines contraindicate dronedarone in patients with NYHA Class III or IV HF, recently decompensated HF, or EF below 35% (some guidelines use 40%). This patient has an EF of 34% and established HFrEF, placing him squarely within the contraindicated population regardless of current symptom class.
Option A: Option A incorrectly restricts the ANDROMEDA contraindication to NYHA Class IV, guidelines apply it to Class III and IV and to recently decompensated patients regardless of current class.
Option B: Option B incorrectly states that ATHENA enrolled patients with significantly reduced EF: ATHENA enrolled patients with non-permanent AF without severe HF; it does not provide evidence to support dronedarone in patients with EF below 35%.
Option D: Option D incorrectly states that the EF threshold for the ANDROMEDA contraindication is 25%: the ANDROMEDA trial enrolled patients with EF below or around 35%, and guidelines set the contraindication threshold at approximately 35 to 40% EF with any recent decompensation.
Option E: Option E incorrectly states that the PALLAS contraindication is the only relevant constraint and that ejection fraction is irrelevant: the ANDROMEDA contraindication applies independently of AF type and is based on ejection fraction and heart failure status.
20. Which of the following correctly describes the initiation requirements for sotalol, including the baseline QTc threshold, monitoring duration, and the patient factors that most increase torsades de pointes risk during initiation?
A) Sotalol may be initiated as an outpatient with a baseline QTc below 500 ms; weekly ECG monitoring for the first month is required, and the primary risk factors are hepatic impairment and concurrent use of CYP3A4 inhibitors
B) Sotalol requires 24-hour in-hospital monitoring at initiation with a baseline QTc below 480 ms; the primary risk factors for torsades de pointes are hypertension and left ventricular hypertrophy rather than electrolyte abnormalities
C) Sotalol requires in-hospital initiation for 5 days with a baseline QTc below 420 ms; the primary risk factor is concurrent use of other beta-blockers, which amplifies the Class II component and creates excessive bradycardia
D) Sotalol may be initiated in a monitored outpatient setting with baseline QTc below 470 ms if the patient has no prior history of torsades de pointes: the 3-day in-hospital requirement applies only to patients with prior TdP or QTc above 450 ms at baseline
E) Sotalol requires initiation or re-initiation in a monitored inpatient setting for a minimum of 3 days with continuous telemetry; baseline QTc must be below 450 ms, and TdP risk is amplified by QTc prolongation at any point during initiation, bradycardia, hypokalemia, hypomagnesemia, renal impairment, and female sex
ANSWER: E
Rationale:
Sotalol's mandatory in-hospital initiation requirement reflects its 2 to 4% TdP risk, which is highest during the first several days of therapy as the drug reaches steady-state and QTc effects are most pronounced. Guidelines require a minimum of 3 days of continuous telemetry monitoring with QTc assessment after each dose. The baseline QTc must be below 450 ms to initiate, if QTc exceeds 500 ms at any point during initiation, the dose should be reduced or the drug discontinued. Risk factors for TdP during sotalol initiation include: QTc prolongation, bradycardia, hypokalemia, hypomagnesemia, renal impairment (through drug accumulation), and female sex (women have a higher baseline QTc and greater sensitivity to IKr-blocking drugs).
Option A: Option A incorrectly states that sotalol can be initiated as an outpatient, in-hospital initiation is mandatory, and the QTc threshold and monitoring requirements described are incorrect.
Option B: Option B incorrectly states that 24-hour monitoring is sufficient and sets the QTc threshold at 480 ms: the standard requirement is 3 days of monitoring with a baseline QTc below 450 ms, and the primary electrolyte risk factors are excluded from Option B.
Option C: Option C incorrectly states that 5-day monitoring is required and sets the QTc threshold at 420 ms: both values are incorrect, and incorrectly identifies concurrent beta-blocker use as the primary TdP risk factor.
Option D: Option D incorrectly states that outpatient initiation is acceptable for patients without prior TdP history: the 3-day in-hospital requirement applies to all patients initiating or re-initiating sotalol, not only to those with prior TdP.
21. Which of the following correctly characterizes ibutilide's torsades de pointes risk relative to other Class III agents and the monitoring requirements that follow from that risk?
A) Ibutilide carries a TdP risk of less than 1%, lower than all other Class III agents, because its activation of slow inward sodium current produces APD prolongation that is less heterogeneous across ventricular layers than pure IKr blockade
B) Ibutilide carries the highest TdP risk among Class III agents at 4 to 8%, requiring continuous cardiac monitoring for at least 4 hours after administration or until QTc returns to baseline, with resuscitation equipment immediately available throughout
C) Ibutilide carries a TdP risk equivalent to dofetilide (1 to 3%) but requires longer post-infusion monitoring because its IV route produces faster peak plasma levels than oral dofetilide dosing
D) Ibutilide's TdP risk is entirely eliminated by correcting serum potassium above 4.5 mEq/L and magnesium above 2.5 mg/dL before administration, once these thresholds are met, post-infusion monitoring beyond 30 minutes is not required
E) Ibutilide carries a TdP risk of 4 to 8% but monitoring is required for only 60 minutes post-infusion because its half-life is under 10 minutes and QTc returns to baseline rapidly in all patients once the infusion is stopped
ANSWER: B
Rationale:
Ibutilide has the highest TdP risk among all Class III agents, at approximately 4 to 8% of treated patients. This risk requires continuous cardiac monitoring for at least 4 hours after administration or until QTc has returned to baseline, whichever is longer. Resuscitation equipment, including a defibrillator, must be immediately available throughout the monitoring period. Electrolyte correction before administration (potassium at or above 4.0 mEq/L, magnesium at or above 2.0 mg/dL) is required but does not eliminate TdP risk.
Option A: Option A incorrectly states that ibutilide's TdP risk is below 1%: this is the approximate rate for amiodarone, which has the lowest TdP risk among Class III agents; ibutilide's risk is 4 to 8%.
Option C: Option C incorrectly states that ibutilide's TdP risk is equivalent to dofetilide, dofetilide carries a 1 to 3% TdP risk while ibutilide's is 4 to 8%, making ibutilide significantly higher risk.
Option D: Option D incorrectly states that electrolyte correction eliminates the need for post-infusion monitoring, electrolyte normalization reduces but does not eliminate TdP risk, and the 4-hour monitoring requirement applies regardless of pre-treatment electrolyte status.
Option E: Option E incorrectly states that 60 minutes of monitoring is sufficient, although ibutilide has a short half-life, its APD-prolonging effects on the myocardium persist well beyond plasma clearance, and the 4-hour monitoring requirement reflects this pharmacodynamic persistence.
22. A 67-year-old woman with heart failure with reduced ejection fraction (EF 33%), paroxysmal atrial fibrillation, and no prior myocardial infarction requires rhythm control. Her creatinine clearance is 52 mL/min and baseline QTc is 432 ms. Which of the following correctly identifies the antiarrhythmic agents that are safe to use for rhythm control in this patient, based on established trial evidence and guideline contraindications?
A) Flecainide and propafenone are the preferred first-line agents in HFrEF because their sodium channel blockade stabilizes the ventricle against triggered arrhythmias, and their safety in structural heart disease is supported by the ATHENA trial
B) Sotalol is the preferred agent because its combined Class II and III mechanism provides superior QTc-prolonging efficacy with a safety profile confirmed in the DIAMOND-CHF trial for patients with ejection fraction below 35%
C) Dronedarone is acceptable in this patient because her ejection fraction of 33% is above the ANDROMEDA threshold of 25% and her heart failure is currently compensated: the PALLAS contraindication applies only to permanent AF
D) Amiodarone and dofetilide (dose-adjusted for CrCl 40 to 60 mL/min to 250 mcg twice daily with mandatory in-hospital initiation) are the only antiarrhythmic agents with established safety in HFrEF, flecainide, propafenone, sotalol, and dronedarone are contraindicated or carry mortality signals in this population
E) Any Class III agent is acceptable in patients with HFrEF provided the QTc is below 450 ms at baseline, because the contraindications in structural heart disease apply specifically to Class I agents and do not extend to the Class III drug class as a whole
ANSWER: D
Rationale:
In heart failure with reduced ejection fraction, antiarrhythmic drug selection is severely restricted by safety evidence. Flecainide and propafenone are contraindicated: the CAST trial demonstrated increased mortality with Class Ic agents in structural heart disease, and this contraindication extends beyond post-MI to any significant structural heart disease including HFrEF. Sotalol should be avoided in patients with EF below 40% due to its negative inotropic beta-blocking effect and the mortality signal from the SWORD trial with d-sotalol. Dronedarone is contraindicated given her EF of 33% and history of HFrEF, driven by the ANDROMEDA excess mortality signal. Amiodarone and dofetilide are the only two agents with established safety in HFrEF, DIAMOND-CHF for dofetilide and extensive clinical evidence for amiodarone. Dofetilide requires dose adjustment to 250 mcg twice daily for CrCl 40 to 60 mL/min and mandatory in-hospital initiation with QTc monitoring.
Option A: Option A incorrectly states that flecainide and propafenone are preferred in HFrEF: they are contraindicated in structural heart disease based on CAST, and ATHENA studied dronedarone, not Class Ic agents.
Option B: Option B incorrectly attributes dofetilide's HFrEF safety data to sotalol, DIAMOND-CHF studied dofetilide, not sotalol, and sotalol is avoided in significant LV dysfunction.
Option C: Option C incorrectly states the ANDROMEDA EF threshold is 25% and that compensated status overrides the contraindication, guidelines set the threshold at approximately 35 to 40% and apply the contraindication regardless of current compensation status.
Option E: Option E incorrectly generalizes that all Class III agents are safe in HFrEF provided QTc is acceptable, sotalol and dronedarone carry specific mortality signals in this population that are independent of QTc.
BEFORE YOU MOVE ON
You have now worked through the foundational pharmacology of Class III antiarrhythmic agents. The key framework to carry forward is a drug-by-drug safety matrix built around two axes: ejection fraction and renal function. Amiodarone is the only agent safe in virtually all cardiac substrates, but its multi-organ toxicity burden demands systematic monitoring and a genuine risk-benefit calculation before initiating long-term therapy. Dofetilide and amiodarone are the only two agents proven safe in HFrEF: this is a hard clinical rule, not a guideline preference. Sotalol is renally dependent in a way that is absolute: CrCl below 40 mL/min is a contraindication, not a dose-adjustment opportunity. Ibutilide belongs in the acute setting only, carries the highest TdP risk of the class, and demands 4 hours of post-infusion monitoring. Dronedarone's contraindications in permanent AF and HFrEF are driven by trial evidence showing excess mortality: PALLAS and ANDROMEDA are not theoretical concerns but stopped trials. In Tier 1 you will apply this framework to patient scenarios requiring drug selection, monitoring decisions, and interaction management. The questions will assume you can immediately exclude contraindicated agents and move directly to comparing the acceptable options for a given patient profile.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.